Proteome analysis of adrenal cortical tumors

References

• Else T, Kim AC, Sabolch A, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35(2):282–326.
   PubMed Web of Science ®Google Scholar
• Lehmann T, Wrzesinski T. The molecular basis of adrenocortical cancer. Cancer Genet. 2012;205(4):131–137.
   PubMed Web of Science ®Google Scholar
• Libe R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer. 2007;14(1):13–28.
   PubMed Web of Science ®Google Scholar
• Stigliano A, Cerquetti L, Sampaoli C, et al. Current and emerging therapeutic options in adrenocortical cancer treatment. J Oncol. 2012;408131:2012.
   Google Scholar
• Maehana T, Tanaka T, Itoh N, et al. Clinical outcomes of surgical treatment and longitudinal non-surgical observation of patients with subclinical Cushing’s syndrome and nonfunctioning adrenocortical adenoma. Indian J Urol. 2012;28(2):179–183.
   PubMedGoogle Scholar
• Zeiger MA, Thompson GB, Duh QY, et al. The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract. 2009;15(Suppl 1):1–20.
   PubMedGoogle Scholar
• Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol. 2009;27(27):4619–4629.
   PubMed Web of Science ®Google Scholar
• Balasubramaniam S, Fojo T. Practical considerations in the evaluation and management of adrenocortical cancer. Semin Oncol. 2010;37(6):619–626.
   PubMed Web of Science ®Google Scholar
• Zheng S, Cherniack AD, Dewal N, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016;29(5):723–736.
   PubMed Web of Science ®Google Scholar
• Poli G, Ceni E, Armignacco R, et al. 2D-DIGE proteomic analysis identifies new potential therapeutic targets for adrenocortical carcinoma. Oncotarget. 2015;6(8):5695–5706.
   PubMed Web of Science ®Google Scholar
• Tiu SC, Chan AO, Taylor NF, et al. Use of urinary steroid profiling for diagnosing and monitoring adrenocortical tumours. Hong Kong Med J. 2009;15(6):463–470.
   PubMedGoogle Scholar
• Ross JS, Wang K, Rand JV, et al. Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies. J Clin Pathol. 2014;67(11):968–973.
   PubMed Web of Science ®Google Scholar
• Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol. 2003;169(1):5–11.
   PubMed Web of Science ®Google Scholar
• Zografos GC, Driscoll DL, Karakousis CP, et al. Adrenal adenocarcinoma: a review of 53 cases. J Surg Oncol. 1994;55(3):160–164.
   PubMed Web of Science ®Google Scholar
• Kloos RT, Gross MD, Francis IR, et al. Incidentally discovered adrenal masses. Endocr Rev. 1995;16(4):460–484.
   PubMed Web of Science ®Google Scholar
• Lerario AM, Moraitis A, Hammer GD. Genetics and epigenetics of adrenocortical tumors. Mol Cell Endocrinol. 2014;386(1–2):67–84.
   PubMed Web of Science ®Google Scholar
• McNicol AM. Diagnostic and molecular aspects of adrenal cortical tumors. Semin Diagn Pathol. 2013;30(3):197–206.
   PubMed Web of Science ®Google Scholar
• Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007;356(6):601–610.
   PubMed Web of Science ®Google Scholar
• Arnold DT, Reed JB, Burt K. Evaluation and management of the incidental adrenal mass. Proc (Bayl Univ Med Cent). 2003;16(1):7–12.
   PubMedGoogle Scholar
• Lloyd RV. Adrenal cortical tumors, pheochromocytomas and paragangliomas. Mod Pathol. 2011;24(Suppl 2):S58–S65.
   PubMed Web of Science ®Google Scholar
• Jia AH, Du HQ, Fan MH, et al. Clinical and pathological analysis of 116 cases of adult adrenal cortical adenoma and literature review. Onco Targets Ther. 2015;8:1251–1257.
   PubMedGoogle Scholar
• Pinto A, Barletta JA. Adrenal tumors in adults. Surg Pathol Clin. 2015;8(4):725–749.
   PubMedGoogle Scholar
• Gicquel C, Baudin E, Lebouc Y, et al. Adrenocortical carcinoma. Ann Oncology. 1997;8(5):423–427.
   PubMed Web of Science ®Google Scholar
• Ayala-Ramirez M, Jasim S, Feng L, et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013;169(6):891–899.
   PubMed Web of Science ®Google Scholar
• Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol. 1989;13(3):202–206.
   PubMed Web of Science ®Google Scholar
• Aubert S, Wacrenier A, Leroy X, et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol. 2002;26(12):1612–1619.
   PubMed Web of Science ®Google Scholar
• Hough AJ, Hollifield JW, Page DL, et al. Prognostic factors in adrenal cortical tumors. A mathematical analysis of clinical and morphologic data. Am J Clin Pathol. 1979;72(3):390–399.
   PubMed Web of Science ®Google Scholar
• Van Slooten H, Schaberg A, Smeenk D, et al. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer. 1985;55(4):766–773.
   PubMed Web of Science ®Google Scholar
• Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311–322.
   PubMed Web of Science ®Google Scholar
• Iino K, Sasano H, Yabuki N, et al. DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas. Mod Pathol. 1997;10(9):901–907.
   PubMed Web of Science ®Google Scholar
• Soon PS, Gill AJ, Benn DE, et al. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocr Relat Cancer. 2009;16(2):573–583.
   PubMed Web of Science ®Google Scholar
• Gupta D, Shidham V, Holden J, et al. Value of topoisomerase II alpha, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms. Appl Immunohistochem Mol Morphol. 2001;9(3):215–221.
   PubMedGoogle Scholar
• Nakazumi H, Sasano H, Iino K, et al. Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms. Mod Pathol. 1998;11(12):1165–1170.
   PubMed Web of Science ®Google Scholar
• Sbiera S, Kroiss M, Thamm T, et al. Survivin in adrenocortical tumors – pathophysiological implications and therapeutic potential. Horm Metab Res. 2013;45(2):137–146.
   PubMed Web of Science ®Google Scholar
• Sbiera S, Schmull S, Assie G, et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab. 2010;95(10):E161–E171.
   PubMed Web of Science ®Google Scholar
• Duregon E, Volante M, Giorcelli J, et al. Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates. Hum Pathol. 2013;44(5):822–828.
   PubMed Web of Science ®Google Scholar
• Gaujoux S, Grabar S, Fassnacht M, et al. Beta-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res. 2011;17(2):328–336.
   PubMed Web of Science ®Google Scholar
• Fenske W, Volker HU, Adam P, et al. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer. 2009;16(3):919–928.
   PubMed Web of Science ®Google Scholar
• Waldmann J, Feldmann G, Slater EP, et al. Expression of the zinc-finger transcription factor Snail in adrenocortical carcinoma is associated with decreased survival. Br J Cancer. 2008;99(11):1900–1907.
   PubMed Web of Science ®Google Scholar
• Yang MS, Wang HS, Wang BS, et al. A comparative proteomic study identified calreticulin and prohibitin up-regulated in adrenocortical carcinomas. Diagn Pathol. 2013;8:58.
   PubMed Web of Science ®Google Scholar
• Kjellin H, Johansson H, Hoog A, et al. Differentially expressed proteins in malignant and benign adrenocortical tumors. Plos One. 2014;9(2):e87951.
   PubMed Web of Science ®Google Scholar
• Wang C, Sun Y, Wu H, et al. Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers. Histopathology. 2014;64(4):567–576.
   PubMed Web of Science ®Google Scholar
• Ye J, Qi Y, Wang W, et al. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas. Endocrine. 2012;41(3):479–486.
   PubMed Web of Science ®Google Scholar
• Szajerka A, Dziegiel P, Szajerka T, et al. Immunohistochemical evaluation of metallothionein, Mcm-2 and Ki-67 antigen expression in tumors of the adrenal cortex. Anticancer Res. 2008;28(5B):2959–2965.
   PubMed Web of Science ®Google Scholar
• Kiiveri S, Liu J, Arola J, et al. Transcription factors GATA-6, SF-1, and cell proliferation in human adrenocortical tumors. Mol Cell Endocrinol. 2005;233(1–2):47–56.
   PubMed Web of Science ®Google Scholar
• Giordano TJ, Thomas DG, Kuick R, et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol. 2003;162(2):521–531.
   PubMed Web of Science ®Google Scholar
• de Fraipont F, El Atifi M, Cherradi N, et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab. 2005;90(3):1819–1829.
   PubMed Web of Science ®Google Scholar
• Slater EP, Diehl SM, Langer P, et al. Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur J Endocrinol. 2006;154(4):587–598.
   PubMed Web of Science ®Google Scholar
• Velazquez-Fernandez D, Laurell C, Geli J, et al. Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery. 2005;138(6):1087–1094.
   PubMed Web of Science ®Google Scholar
• Fonseca AL, Kugelberg J, Starker LF, et al. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Genes Chromosomes Cancer. 2012;51(10):949–960.
   PubMed Web of Science ®Google Scholar
• Assie G, Letouze E, Fassnacht M, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014;46(6):607–612.
   PubMed Web of Science ®Google Scholar
• Gara SK, Wang Y, Patel D, et al. Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples. Nucleic Acids Res. 2015;43(19):9327–9339.
   PubMed Web of Science ®Google Scholar
• Tombol Z, Szabo PM, Molnar V, et al. Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocr Relat Cancer. 2009;16(3):895–906.
   PubMed Web of Science ®Google Scholar
• Soon PS, Tacon LJ, Gill AJ, et al. miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res. 2009;15(24):7684–7692.
   PubMed Web of Science ®Google Scholar
• Patterson EE, Holloway AK, Weng J, et al. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer. 2011;117(8):1630–1639.
   PubMed Web of Science ®Google Scholar
• Schmitz KJ, Helwig J, Bertram S, et al. Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours. J Clin Pathol. 2011;64(6):529–535.
   PubMed Web of Science ®Google Scholar
• Singh P, Soon PS, Feige JJ, et al. Dysregulation of microRNAs in adrenocortical tumors. Mol Cell Endocrinol. 2012;351(1):118–128.
   PubMed Web of Science ®Google Scholar
• Minowada S, Kinoshita K, Hara M, et al. Measurement of urinary steroid profile in patients with adrenal tumor as a screening method for carcinoma. Endocrinol Jpn. 1985;32(1):29–37.
   PubMedGoogle Scholar
• Arlt W, Biehl M, Taylor AE, et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab. 2011;96(12):3775–3784.
   PubMed Web of Science ®Google Scholar
• Kotlowska A, Sworczak K, Stepnowski P. Urine metabolomics analysis for adrenal incidentaloma activity detection and biomarker discovery. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(5–6):359–363.
   PubMed Web of Science ®Google Scholar
• Kotlowska A, Malinski E, Sworczak K, et al. The urinary steroid profile in patients diagnosed with adrenal incidentaloma. Clin Biochem. 2009;42(6):448–454.
   PubMed Web of Science ®Google Scholar
• Kerkhofs TM, Kerstens MN, Kema IP, et al. Diagnostic value of urinary steroid profiling in the evaluation of adrenal tumors. Horm Cancer. 2015;6(4):168–175.
   PubMed Web of Science ®Google Scholar
• Tremoen NH, Fowler PA, Ropstad E, et al. Exposure to the three structurally different PCB congeners (PCB 118, 153, and 126) results in decreased protein expression and altered steroidogenesis in the human adrenocortical carcinoma cell line H295R. J Toxicol Environ Health A. 2014;77(9–11):516–534.
   PubMed Web of Science ®Google Scholar
• Sbiera S, Leich E, Liebisch G, et al. Mitotane inhibits sterol-O-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology. 2015;156(11):3895–3908.
   PubMed Web of Science ®Google Scholar
• Dransfield DT, Cohen EH, Chang Q, et al. A human monoclonal antibody against insulin-like growth factor-II blocks the growth of human hepatocellular carcinoma cell lines in vitro and in vivo. Mol Cancer Ther. 2010;9(6):1809–1819.
   PubMed Web of Science ®Google Scholar
• Gallicchio MA, van Sinderen M, Bach LA. Insulin-like growth factor binding protein-6 and CCI-779, an ester analogue of rapamycin, additively inhibit rhabdomyosarcoma growth. Horm Metab Res. 2003;35(11–12):822–827.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang H, Zhao Y, et al. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111). FEBS Lett. 2013;587(22):3681–3686.
   PubMed Web of Science ®Google Scholar
• Huang FK, Han S, Xing B, et al. Targeted inhibition of fascin function blocks tumour invasion and metastatic colonization. Nat Commun. 2015;6:7465.
   PubMed Web of Science ®Google Scholar
• Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006;91(7):2650–2655.
   PubMed Web of Science ®Google Scholar
• Stigliano A, Cerquetti L, Borro M, et al. Modulation of proteomic profile in H 295R adrenocortical cell line induced by mitotane. Endocr Relat Cancer. 2008;15(1):1–10.
   PubMed Web of Science ®Google Scholar